![]() |
|
|
Vol. 26, Issue 7, 661-669, July 1998
INSERM U26 Département de Pharmacocinétique de la
Faculté de Pharmacie (G.H., M.B.-R., J.M.S.) and
Département de Biodynamique et de Métabolisme et
Pharmacocinétique, Rhône Poulenc-Rorer (P.G.)
Colchicine-specific goat IgG and Fab fragments were cationized by
covalent coupling of hexamethylenediamine. The immunoreactivity of
antibodies was not changed following cationization. The interaction of
125I-radiolabeled native (nIgG and nFab) and
cationized immunoglobulin G (cIgG) and Fab fragments (cFab) with liver
was investigated using isolated perfused rat liver (IPRL) and isolated
rat hepatic parenchymal cells (PCs) and nonparenchymal cells (NPCs) in
suspension. I-cIgG or
125I-cFab were more rapidly cleared from the
perfusate than the corresponding native proteins. Both cIgG and cFab
declined biexponentially over time in the perfusate. In contrast, the
native IgG and Fab decreased monoexponentially. The half-lives of the
initial and terminal phases were 5.2 ± 1.6 min and 355.1 ± 17.2 min for cIgG and 14.7 ± 3.4 min and 552.4 ± 23.7 min
for cFab. The terminal half-lives of nIgG (467.4 ± 11.6 min) and
nFab (880.1 ± 39.6 min) were longer than those of cationized
molecules. The biliary protein extraction ratio of cationized IgG and
Fab was greater than that of native IgG and Fab: 0.13% (cIgG), 0.02%
(nIgG), 0.23% (cFab), and 0.17% (nFab). The uptake of cIgG and cFab
by both PCs and NPCs was dose-dependent and was about 6-fold and 8-fold
higher than that of their native counterparts, respectively. Throughout
the experiment, liver viability was determined, and no toxicity was
observed according to physiological analysis (bile flow rate, portal
vein pressure, and pH) and biochemical analysis (glucose and hepatic
enzymes: alanine transaminase, aspartate transaminase, lactate
dehydrogenase) in perfusate.
This article has been cited by other articles:
![]() |
N. J. Patel, M. J. Zamek-Gliszczynski, P. Zhang, Y.-H. Han, P. L. M. Jansen, P. J. Meier, B. Stieger, and K. L. R. Brouwer Phenobarbital Alters Hepatic Mrp2 Function by Direct and Indirect Interactions Mol. Pharmacol., July 1, 2003; 64(1): 154 - 159. [Abstract] [Full Text] [PDF] |
||||